Heart Failure With Preserved Ejection Fraction Clinical Trials 2023
Heart Failure With Preserved Ejection Fraction research studies recruiting patients in 2023 need your help. Receive premium care & cutting edge treatments by enrolling in heart failure with preserved ejection fraction clinical trials today.
Cardiac Contractility Modulation
CCM Therapy for Heart Failure
Recruiting0 awards7 criteria
Mesa, Arizona
This trial tests a device that helps the heart pump better in patients with moderate heart failure. It targets those whose heart's pumping ability is moderately reduced. The device works by giving the heart small electrical boosts. Several new devices for the treatment of heart failure patients have been introduced and are increasingly used in medical practice or are under evaluation.
Gene Therapy
Gene Therapy for Diastolic Heart Failure
Recruiting1 awardPhase 1
Durham, North Carolina
This trial tests a new gene therapy for people with a type of heart failure where the heart struggles to relax and fill with blood. The therapy is given through an infusion directly into the heart. Researchers want to see if it helps the heart work better and if it is safe for patients. Gene therapy has shown promise in treating heart failure, with improvements making it safer and more effective.
Angiotensin Receptor-Neprilysin Inhibitor
Sacubitril-Valsartan for Heart Failure in HIV
Recruiting2 awardsPhase 2
Boston, Massachusetts
This trial is testing a medication called sacubitril/valsartan in people with HIV who show early signs of heart changes. The medication aims to block a harmful hormone and increase a protective one to prevent heart problems. The study will see if this treatment can improve heart health in these patients.
Angiotensin Receptor Blocker/Neprilysin Inhibitor
LCZ696 for Heart Failure
Recruiting2 awardsPhase 4
Nashville, Tennessee
This trial is testing the hypothesis that the effects of LCZ696 on blood pressure, natriuresis, and diuresis at initiation are due to the inhibition of neprilysin, which degrades endogenous bradykinin. The study will enroll 80 subjects with stable heart failure who will be given LCZ696 50 mg and either the bradykinin B2 receptor antagonist icatibant or placebo vehicle in random order (double-blind).
Popular Filters
Trials for Left Ventricular Dysfunction Patients
Not applicable
Aortix Device for Heart Failure
Recruiting1 award5 criteria
Wichita, Kansas
This trial tests a device called Aortix that helps the heart pump blood better. It targets patients with severe heart failure who don't get better with usual treatments. The device works by helping the heart move blood more efficiently.
Phytochemical
Sulforaphane for Heart Failure
Recruiting0 awardsPhase 1 & 2
Lubbock, Texas
This trial tests if a broccoli extract called Sulforaphane can help older adults with a certain type of heart failure. The extract may protect the heart by reducing damage and inflammation. Sulforaphane is a compound derived from vegetables like broccoli, known for its anti-inflammatory and antioxidant properties.
Trials for Right Ventricular Dysfunction Patients
Not applicable
Aortix Device for Heart Failure
Recruiting1 award5 criteria
Wichita, Kansas
This trial tests a device called Aortix that helps the heart pump blood better. It targets patients with severe heart failure who don't get better with usual treatments. The device works by helping the heart move blood more efficiently.
Phytochemical
Sulforaphane for Heart Failure
Recruiting0 awardsPhase 1 & 2
Lubbock, Texas
This trial tests if a broccoli extract called Sulforaphane can help older adults with a certain type of heart failure. The extract may protect the heart by reducing damage and inflammation. Sulforaphane is a compound derived from vegetables like broccoli, known for its anti-inflammatory and antioxidant properties.
Trials With No Placebo
Not applicable
Aortix Device for Heart Failure
Recruiting1 award5 criteria
Wichita, Kansas
This trial tests a device called Aortix that helps the heart pump blood better. It targets patients with severe heart failure who don't get better with usual treatments. The device works by helping the heart move blood more efficiently.
Virus Therapy
NAN-101 for Heart Failure
Recruiting1 awardPhase 1
Minneapolis, Minnesota
This trial tests a new heart treatment given directly into the heart's blood vessels. It aims to help patients with severe heart failure who have significant symptoms and limited physical activity. The treatment is designed to improve heart function and quality of life.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.